IMKELDI vs TASIGNA

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 23, 2026·How we rate

Possible drug interaction. IMKELDI and TASIGNA are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	IMKELDI	TASIGNA
Rating	New	70/100
Pharmacy pays	~$25.80 /30	—
Type	RX	RX
Active ingredient	IMATINIB MESYLATE	NILOTINIB HYDROCHLORIDE
Manufacturer	Shorla Oncology	Novartis
Dosage forms	Solution	Capsule
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	Boxed warning
Treats	Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome	Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia

imkeldi tasigna

Rating

New

70/100

Pharmacy pays

~$25.80 /30

—

Type

Active ingredient

IMATINIB MESYLATE

NILOTINIB HYDROCHLORIDE

Manufacturer

Shorla Oncology

Novartis

Dosage forms

Solution

Capsule

Drug class

Kinase Inhibitor

Boxed warning

None

Boxed warning

Treats

Lymphoid Leukemia, Myeloid Leukemia, Hypereosinophilic Syndrome

Accelerated Phase Myeloid Leukemia, Chronic-Phase Myeloid Leukemia

Frequently asked questions

What is the difference between Imkeldi and Tasigna?

Imkeldi contains Imatinib Mesylate, while Tasigna contains Nilotinib Hydrochloride — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.